循环肿瘤 DNA 为非小细胞肺癌的治疗反应提供了先见之明。
Circulating Tumor DNA Provides a Sneak Peek into Treatment Responses in Non-Small Cell Lung Cancer.
机构信息
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
出版信息
Cancer Res. 2019 Mar 15;79(6):1038-1040. doi: 10.1158/0008-5472.CAN-19-0231.
Abstract
Circulating tumor DNA (ctDNA) holds great promise as a noninvasive diagnostic tool to guide treatment for patients with lung cancer. Two studies by Phallen and colleagues and Anagnostou and colleagues correlated sensitive measures of ctDNA with clinical responses to tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors, respectively, in patients with non-small cell lung cancer (NSCLC). Together, these studies further highlight the potential clinical utility of serial ctDNA monitoring in patients with NSCLC undergoing treatment with both targeted therapies and immunotherapies..
摘要
循环肿瘤 DNA（ctDNA）作为一种非侵入性诊断工具，有望指导肺癌患者的治疗。Phallen 及其同事和 Anagnostou 及其同事的两项研究分别将 ctDNA 的敏感测量结果与非小细胞肺癌（NSCLC）患者对酪氨酸激酶抑制剂（TKI）和免疫检查点抑制剂的临床反应相关联。这两项研究共同进一步强调了在接受靶向治疗和免疫治疗的 NSCLC 患者中进行连续 ctDNA 监测的潜在临床应用。
相似文献
1
Circulating Tumor DNA Provides a Sneak Peek into Treatment Responses in Non-Small Cell Lung Cancer.循环肿瘤 DNA 为非小细胞肺癌的治疗反应提供了先见之明。
Cancer Res. 2019 Mar 15;79(6):1038-1040. doi: 10.1158/0008-5472.CAN-19-0231.
2
Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.先前接受过酪氨酸激酶抑制剂治疗的表皮生长因子受体（EGFR）突变型非小细胞肺癌患者接受奥希替尼治疗后的循环肿瘤DNA分析
Lung Cancer. 2020 Jul;145:173-180. doi: 10.1016/j.lungcan.2020.04.039. Epub 2020 May 11.
3
[Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].[利用二代测序检测表皮生长因子受体-酪氨酸激酶抑制剂复发的非小细胞肺癌患者循环肿瘤DNA并分析耐药机制]
Zhonghua Bing Li Xue Za Zhi. 2018 Dec 8;47(12):904-909. doi: 10.3760/cma.j.issn.0529-5807.2018.12.002.
4
Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC).循环肿瘤 DNA（ctDNA）在检测非小细胞肺癌（NSCLC）中原始致敏和耐药 EGFR 突变中的应用。
Curr Oncol. 2022 Feb 14;29(2):1107-1116. doi: 10.3390/curroncol29020094.
5
Targeted Sequencing of Circulating Cell Free DNA Can Be Used to Monitor Therapeutic Efficacy of Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients.循环游离 DNA 的靶向测序可用于监测非小细胞肺癌患者酪氨酸激酶抑制剂的治疗效果。
Cancer Genomics Proteomics. 2020 Jul-Aug;17(4):417-423. doi: 10.21873/cgp.20200.
6
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.一项评估奥希替尼用于经液体活检检测到 EGFR T790M 突变的非小细胞肺癌二线治疗的 II 期临床试验：LiquidLung-O-队列 2。
Cancer Res Treat. 2019 Apr;51(2):777-787. doi: 10.4143/crt.2018.387. Epub 2018 Sep 7.
7
Correlation Between Circulating Tumor DNA Levels and Response to Tyrosine Kinase Inhibitors (TKI) Treatment in Non-Small Cell Lung Cancer.循环肿瘤 DNA 水平与非小细胞肺癌酪氨酸激酶抑制剂 (TKI) 治疗反应的相关性。
Med Sci Monit. 2017 Jul 25;23:3627-3634. doi: 10.12659/msm.902265.
8
Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer.循环肿瘤 DNA 清除预测一线酪氨酸激酶抑制剂治疗晚期表皮生长因子受体突变型非小细胞肺癌的临床反应。
Lung Cancer. 2020 Mar;141:37-43. doi: 10.1016/j.lungcan.2019.12.016. Epub 2019 Dec 30.
9
Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.循环肿瘤 DNA 分析在 EGFR 抑制剂治疗非小细胞肺癌患者中的作用。
Oncology. 2022;100(4):228-237. doi: 10.1159/000516813. Epub 2022 Feb 23.
10
Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.循环肿瘤 DNA：一种监测 EGFR-TKIs 治疗 NSCLC 患者耐药的新型生物标志物。
Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188363. doi: 10.1016/j.bbcan.2020.188363. Epub 2020 Apr 8.
引用本文的文献
1
Inhibition of CRY2 by STAT3/miRNA-7-5p Promotes Osteoblast Differentiation through Upregulation of CLOCK/BMAL1/P300 Expression.STAT3/miRNA-7-5p对CRY2的抑制通过上调CLOCK/BMAL1/P300表达促进成骨细胞分化。
Mol Ther Nucleic Acids. 2020 Mar 6;19:865-876. doi: 10.1016/j.omtn.2019.12.020. Epub 2019 Dec 24.
本文引用的文献
1
Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer.早期无创检测非小细胞肺癌对靶向治疗的反应。
Cancer Res. 2019 Mar 15;79(6):1204-1213. doi: 10.1158/0008-5472.CAN-18-1082. Epub 2018 Dec 20.
2
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.在非小细胞肺癌的免疫检查点阻断期间肿瘤和免疫反应的动力学
Cancer Res. 2019 Mar 15;79(6):1214-1225. doi: 10.1158/0008-5472.CAN-18-1127. Epub 2018 Dec 12.
3
Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab.早期 ctDNA 降低可预测杜伐鲁单抗治疗的肺癌和膀胱癌患者的生存情况。
Clin Cancer Res. 2018 Dec 15;24(24):6212-6222. doi: 10.1158/1078-0432.CCR-18-0386. Epub 2018 Aug 9.
4
Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma.对多发性骨髓瘤的游离 DNA 和循环肿瘤细胞进行全外显子组测序。
Nat Commun. 2018 Apr 27;9(1):1691. doi: 10.1038/s41467-018-04001-5.
5
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.通过循环肿瘤 DNA 早期评估肺癌免疫治疗反应。
Clin Cancer Res. 2018 Apr 15;24(8):1872-1880. doi: 10.1158/1078-0432.CCR-17-1341. Epub 2018 Jan 12.
6
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.纳武利尤单抗免疫治疗期间的肿瘤与微环境演变
Cell. 2017 Nov 2;171(4):934-949.e16. doi: 10.1016/j.cell.2017.09.028. Epub 2017 Oct 12.
7
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.一线纳武利尤单抗用于IV期或复发性非小细胞肺癌
N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.
8
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.肺癌患者接受PD-1靶向治疗后外周血中PD-1+ CD8 T细胞的增殖情况。
Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998. doi: 10.1073/pnas.1705327114. Epub 2017 Apr 26.
9
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
10
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.利用游离血浆DNA的定量下一代基因分型对EGFR突变型肺癌的反应和耐药性进行无创检测。
Clin Cancer Res. 2014 Mar 15;20(6):1698-1705. doi: 10.1158/1078-0432.CCR-13-2482. Epub 2014 Jan 15.
Zotero 插件